Hussain M
Section of Hematology/Oncology, VA Medical Center, Allen Park, Michigan 48101, USA.
Prostate Suppl. 1996;6:26-30.
Prostate cancer has become one of the most important national health problems, as its incidence increases yearly. Conventionally, single-modality local therapy has been the standard of care for clinically localized stage disease and systemic therapy, in the form of primary or combined androgen deprivation, is reserved for advanced, usually metastatic, prostate cancer. Despite improvements in local therapy, a significant number of patients with clinically localized prostate cancer will suffer a systemic relapse after potentially curative local therapy and, despite 50 years of experience in hormone therapy, significant survival prolongation for patients with metastatic prostate cancer remains a challenge. This paper explores potential future systemic therapy strategies in the treatment of prostate cancer. Specifically, the role of adjuvant systemic therapy as part of a multimodality treatment approach for localized prostate cancer and alternative applications of hormone and chemohormone therapies for patients with metastatic disease are discussed.
前列腺癌已成为最重要的国民健康问题之一，因为其发病率逐年上升。传统上，单一局部治疗一直是临床局限性疾病的标准治疗方法，而以原发性或联合雄激素剥夺形式的全身治疗则用于晚期（通常为转移性）前列腺癌。尽管局部治疗有所改进，但大量临床局限性前列腺癌患者在接受可能治愈性的局部治疗后仍会出现全身复发，并且尽管激素治疗已有50年的经验，但转移性前列腺癌患者的显著生存延长仍然是一个挑战。本文探讨了前列腺癌治疗中未来潜在的全身治疗策略。具体而言，讨论了辅助全身治疗作为局限性前列腺癌多模式治疗方法一部分的作用，以及激素和化学激素疗法在转移性疾病患者中的替代应用。
